
Merck & Co., Inc.
Merck & Co., Inc. is a United States-based company in the Healthcare sector with a market capitalisation of $360.1B. Its FinScore is 53/100; its highest-scoring layer is Quality (79) and its lowest is Value (23). The shares trade at 113.5x trailing earnings and are up 37% year to date.
Share price performance
About Merck & Co., Inc.
www.merck.comMerck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- HQ
- United States
- Fiscal year-end
- December
- Trading currency
- USD
- Reporting currency
- USD
- Fundamentals updated
- 24 days ago
- Market cap
- $360.1B
- Shares outstanding
- 2.5B
- P/E (TTM)
- 113.5x
- Dividend yield (TTM)
- 2.33%
- Beta (issuer)
- 0.22
- Revenue (latest FY)
- $64.9B
Revenue breakdown
- Pharmaceutical segment89.4%$58.1B
- Animal Health segment9.8%$6.4B
- Other Segments0.8%$515.0M
FinScore
As of 2026-10-19Snapshot
Ownership
As of 2026-06-30Sign up or log in to see Analysis
Analysis for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Merck & Co., Inc. is available to Finryse members. The Overview stays open to everyone; creating an account is free.